Skip to main content
Erschienen in: Tumor Biology 5/2012

01.10.2012 | Research Article

TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk

verfasst von: Gisela Barbisan, Luis Orlando Pérez, Anahí Contreras, Carlos Daniel Golijow

Erschienen in: Tumor Biology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Although the implication of genetic factors in cervical cancer development remains to be elucidated, accumulative epidemiological evidence suggests that polymorphisms of cytokine genes may be involved in the etiology of cervical carcinoma. Tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) are two multifunctional cytokines implicated in inflammation, immunity, and cellular organization, and were proposed to play important roles in cancer biology. In order to determine whether IL-10 -1082 (G/A) and TNF-α -238 (G/A) and -308 (G/A) polymorphisms are associated with susceptibility to cervical cancer, a case–control study of 122 cancer patients and 176 healthy controls was conducted. Cervical samples were genotyped for both TNF-α polymorphisms by PCR-RFLP assay. SNP-1082 from IL-10 gene was genotyped using pyrosequencing technology. The association between cervical cancer risk and the studied SNPs was evaluated by logistic regression. Under univariate analysis, none of these polymorphisms appeared associated with susceptibility of cervical cancer development or HPV infection. However, individuals carrying heterozygous genotype for TNF-α -238 polymorphism seem to be at lower risk for cervical cancer development, with borderline significance (OR = 0.42, P = 0.069), as well as those carrying heterozygous genotypes for IL-10 and TNF-α -238 (OR = 0.40, P = 0.08). In conclusion, these results suggest a potential effect of TNF-α -238 G/A in the reduction of cervical cancer risk in Argentine women, but not TNF-α -308 or IL-10. Larger studies are needed to fully understand the genetic predisposition for the development of cervical cancer.
Literatur
1.
Zurück zum Zitat Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer (2005). Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.CrossRefPubMed Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer (2005). Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.CrossRefPubMed
2.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
3.
Zurück zum Zitat Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.CrossRefPubMed Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.CrossRefPubMed
4.
Zurück zum Zitat Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer. 1999;82:775–81.CrossRefPubMed Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer. 1999;82:775–81.CrossRefPubMed
5.
Zurück zum Zitat Horng JT, Hu KC, Wu LC, et al. Identifying the combination of genetic factors that determine susceptibility to cervical cancer. IEEE Trans Inf Technol Biomed. 2004;8:59–66.CrossRefPubMed Horng JT, Hu KC, Wu LC, et al. Identifying the combination of genetic factors that determine susceptibility to cervical cancer. IEEE Trans Inf Technol Biomed. 2004;8:59–66.CrossRefPubMed
6.
Zurück zum Zitat zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.CrossRefPubMed zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.CrossRefPubMed
7.
Zurück zum Zitat Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst. 1997;89:1285–93.CrossRefPubMed Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst. 1997;89:1285–93.CrossRefPubMed
8.
Zurück zum Zitat Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997;89:245–50.CrossRefPubMed Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997;89:245–50.CrossRefPubMed
9.
Zurück zum Zitat Tartour E, Gey A, Sastsre-Garou X, Lombard Surin I, Mosseri V, Fridman WH. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst. 1998;90:287–94.CrossRefPubMed Tartour E, Gey A, Sastsre-Garou X, Lombard Surin I, Mosseri V, Fridman WH. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst. 1998;90:287–94.CrossRefPubMed
10.
Zurück zum Zitat Tartour E, Pannetier C, Mathiot C, et al. Prognostic value of cytokine and Fc gamma receptor assays in oncology. Immunol Lett. 1995;44:145–8.CrossRefPubMed Tartour E, Pannetier C, Mathiot C, et al. Prognostic value of cytokine and Fc gamma receptor assays in oncology. Immunol Lett. 1995;44:145–8.CrossRefPubMed
11.
Zurück zum Zitat Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;38:423–8.CrossRef Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;38:423–8.CrossRef
12.
Zurück zum Zitat Li H, Groop L, Nilsson A, Weng J, Tuomi T. A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes. J Clin Endocr Metab. 2003;88:2767–74.CrossRefPubMed Li H, Groop L, Nilsson A, Weng J, Tuomi T. A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes. J Clin Endocr Metab. 2003;88:2767–74.CrossRefPubMed
13.
Zurück zum Zitat Pillai S, Bikle DD, Eessalu TE, Aggarwal BB, Elias PM. Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes. J Clin Invest. 1989;83:816–21.CrossRefPubMedPubMedCentral Pillai S, Bikle DD, Eessalu TE, Aggarwal BB, Elias PM. Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes. J Clin Invest. 1989;83:816–21.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barretts metaplasia and cancer: a unique role for TNF alpha. Eur J Cancer Prev. 2001;10:163–6.CrossRefPubMed Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barretts metaplasia and cancer: a unique role for TNF alpha. Eur J Cancer Prev. 2001;10:163–6.CrossRefPubMed
15.
Zurück zum Zitat Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.CrossRefPubMed Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.CrossRefPubMed
16.
Zurück zum Zitat Wilson AG, Symons JA, McDowell TL, McDevitt HQ, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–9.CrossRefPubMedPubMedCentral Wilson AG, Symons JA, McDowell TL, McDevitt HQ, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–9.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol. 1998;54:173–7.CrossRefPubMed Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol. 1998;54:173–7.CrossRefPubMed
18.
Zurück zum Zitat Jang WH, Yang YI, Yea SS, et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41–6.CrossRefPubMed Jang WH, Yang YI, Yea SS, et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41–6.CrossRefPubMed
19.
Zurück zum Zitat Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21:S447–63.CrossRefPubMed Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21:S447–63.CrossRefPubMed
20.
Zurück zum Zitat Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastasic disease. J Biol Regul Homeost Agents. 1992;6:103–7.PubMed Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastasic disease. J Biol Regul Homeost Agents. 1992;6:103–7.PubMed
21.
Zurück zum Zitat Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.CrossRefPubMed Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.CrossRefPubMed
22.
Zurück zum Zitat Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Derm. 2003;120:99–103.CrossRefPubMed Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Derm. 2003;120:99–103.CrossRefPubMed
23.
24.
Zurück zum Zitat Ting Y, Manos MM. Detection and typing of genital human Papillomavirus. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols. San Diego: Academic Pres; 1990. p. 356. Ting Y, Manos MM. Detection and typing of genital human Papillomavirus. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols. San Diego: Academic Pres; 1990. p. 356.
25.
Zurück zum Zitat Evander M, Edlund K, Bodun E, et al. Comparison of a one-step and two-step polimerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol. 1992;30:987–92.PubMedPubMedCentral Evander M, Edlund K, Bodun E, et al. Comparison of a one-step and two-step polimerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol. 1992;30:987–92.PubMedPubMedCentral
26.
Zurück zum Zitat Söderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol. 2005;43:3260–6.CrossRefPubMedPubMedCentral Söderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol. 2005;43:3260–6.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Stanczuk GA, Sibanda EN, Perrey C, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94:792–4.CrossRefPubMed Stanczuk GA, Sibanda EN, Perrey C, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94:792–4.CrossRefPubMed
28.
Zurück zum Zitat Deshpande A, Nolan JP, White PS, et al. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005;191:969–76.CrossRefPubMed Deshpande A, Nolan JP, White PS, et al. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005;191:969–76.CrossRefPubMed
29.
Zurück zum Zitat Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNF alpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol. 2004;92:675–9.CrossRefPubMed Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNF alpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol. 2004;92:675–9.CrossRefPubMed
30.
Zurück zum Zitat Liu L, Yang X, Chen X, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2683–8.CrossRefPubMed Liu L, Yang X, Chen X, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2683–8.CrossRefPubMed
31.
Zurück zum Zitat Badano I, Stietz SM, Schurr TG, et al. Analysis of TNF-α promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2012;53:54–9.CrossRefPubMed Badano I, Stietz SM, Schurr TG, et al. Analysis of TNF-α promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2012;53:54–9.CrossRefPubMed
32.
Zurück zum Zitat Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006;6:24.CrossRefPubMedPubMedCentral Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006;6:24.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:148–53.CrossRefPubMed Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:148–53.CrossRefPubMed
34.
Zurück zum Zitat Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544–8.CrossRefPubMed Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544–8.CrossRefPubMed
35.
Zurück zum Zitat Calhoun ES, McGovern RM, Janney CA, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218–24.PubMed Calhoun ES, McGovern RM, Janney CA, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218–24.PubMed
36.
Zurück zum Zitat Magalhães RF, Biral AC, Pancoto JA, et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol. 2010;49:1133–40.CrossRefPubMed Magalhães RF, Biral AC, Pancoto JA, et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol. 2010;49:1133–40.CrossRefPubMed
37.
Zurück zum Zitat Nedoszytko B, Szczerkowska-Dobosz A, Zabłotna M, Gleń J, Rebała K, Roszkiewicz J. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol. 2007;157:165–7.CrossRefPubMed Nedoszytko B, Szczerkowska-Dobosz A, Zabłotna M, Gleń J, Rebała K, Roszkiewicz J. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol. 2007;157:165–7.CrossRefPubMed
38.
Zurück zum Zitat Gostout BS, Poland GA, Calhoun ES, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol. 2003;88:326–32.CrossRefPubMed Gostout BS, Poland GA, Calhoun ES, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol. 2003;88:326–32.CrossRefPubMed
39.
Zurück zum Zitat Fong CL, Siddiqui AH, Mark DF. Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res. 1994;22:1108–14.CrossRefPubMedPubMedCentral Fong CL, Siddiqui AH, Mark DF. Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res. 1994;22:1108–14.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol. 2000;114:1180–3.CrossRefPubMed kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol. 2000;114:1180–3.CrossRefPubMed
41.
Zurück zum Zitat Matsumoto K, Oki A, Satoh T, et al. Interleukin-10–1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 2010;40:1113–6.CrossRefPubMed Matsumoto K, Oki A, Satoh T, et al. Interleukin-10–1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 2010;40:1113–6.CrossRefPubMed
42.
Zurück zum Zitat Zoodsma M, Nolte IM, Schipper M, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005;15:282–90.CrossRefPubMed Zoodsma M, Nolte IM, Schipper M, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005;15:282–90.CrossRefPubMed
43.
Zurück zum Zitat Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J Carcinog. 2003;2:3.CrossRefPubMedPubMedCentral Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J Carcinog. 2003;2:3.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Szöke K, Szalmás A, Szládek G, et al. IL-10 promoter nt -1082A/G polymorphism and human papillomavirus infection in cytologic abnormalities of the uterine cervix. J Interferon Cytokine Res. 2004;24:245–51.CrossRefPubMed Szöke K, Szalmás A, Szládek G, et al. IL-10 promoter nt -1082A/G polymorphism and human papillomavirus infection in cytologic abnormalities of the uterine cervix. J Interferon Cytokine Res. 2004;24:245–51.CrossRefPubMed
45.
Zurück zum Zitat Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet. 2000;27:241–9.CrossRefPubMed Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet. 2000;27:241–9.CrossRefPubMed
46.
Zurück zum Zitat Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998;6:193–7.CrossRefPubMed Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998;6:193–7.CrossRefPubMed
47.
Zurück zum Zitat Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1090–5.CrossRefPubMed Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1090–5.CrossRefPubMed
48.
Zurück zum Zitat Poli F, Nocco A, Berra S, et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet. 2002;29:237–40.CrossRefPubMed Poli F, Nocco A, Berra S, et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet. 2002;29:237–40.CrossRefPubMed
Metadaten
Titel
TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk
verfasst von
Gisela Barbisan
Luis Orlando Pérez
Anahí Contreras
Carlos Daniel Golijow
Publikationsdatum
01.10.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0408-1

Weitere Artikel der Ausgabe 5/2012

Tumor Biology 5/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.